glp 1 reduces inflammation GLP-1 Receptor Agonists Reduce GLP-1 therapy isn't just about

Semaglutides most common side effect, nausea, occurs in over 40% of patients per other clinical trials

It differs from the modest lean-mass reduction seen during weight loss, where the body adapts to lower energy needs

Incretin has been proposed as a possible new treatment option for AD due to its brain-protective properties

The study emphasizes the necessity of more investigation to comprehend the processes behind these impacts on fracture risk and bone metabolism ( It has been demonstrated that GLP-1 agonists significantly increase the mass of the femur and vertebrae ( In individuals with T2DM, the risk of fractures was assessed using a network meta-analysis and systematic review to determine the relationship between dipeptidyl peptidase-4 inhibitors (DPP-4i), GLP-1 RAs, and sodium-glucose cotransporter-2 inhibitors (SGLT-2i)

DISCLAIMER: THIS INFORMATION HAS NOT BEEN EVALUATED OR ENDORSED BY THE FDA AND SHOULD NOT BE CONSIDERED AS MEDICAL ADVICE

Mechanical and degenerative causes represent the most common etiologies in adults and include: Lumbar strain or sprain from physical activity, poor posture, or occupational factors Degenerative disc disease and facet joint arthropathy Spinal stenosis, particularly in older adults Herniated nucleus pulposus with or without radiculopathy Spondylolisthesis or other structural abnormalities Metabolic and systemic conditions that may coincide with diabetes treatment include: Diabetic radiculoplexus neuropathy (diabetic amyotrophy), which typically presents with severe unilateral thigh/hip pain and weakness rather than primary lower back pain Osteoporosis with vertebral compression fractures, particularly relevant in patients with long-standing diabetes or corticosteroid exposure Infectious causes requiring urgent evaluation include: Spinal epidural abscess Vertebral osteomyelitis/discitis, especially in patients with diabetes, immunosuppression, or intravenous drug use Visceral referred pain should be considered, especially given semaglutide's gastrointestinal effects: Nephrolithiasis (kidney stones) Pyelonephritis or other urinary tract pathology Pancreatitis (though typically mid-back pain) Cholecystitis or biliary colic Weight loss-related factors specific to patients on semaglutide may include altered biomechanics, increased physical activity without proper conditioning, or changes in body composition affecting spinal support structures